1. Market Research
  2. > Telik, Inc. – Product Pipeline Review – 2013

Telik, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 54 pages

Telik, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Telik, Inc. - Product Pipeline Review - 2013” provides data on the Telik, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Telik, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Telik, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Telik, Inc. - Brief Telik, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Telik, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Telik, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Telik, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Telik, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Telik, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Telik, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Telik, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Telik, Inc. and identify potential opportunities in those areas.

Table Of Contents

Telik, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Telik, Inc. Snapshot 5
Telik, Inc. Overview 5
Key Information 5
Key Facts 5
Telik, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Telik, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Telik, Inc. - Pipeline Products Glance 12
Telik, Inc. - Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
Telik, Inc. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Telik, Inc. - Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Telik, Inc. - Drug Profiles 16
canfosfamide hydrochloride 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
DNA Methyltransferase Inhibitor 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
ezatiostat hydrochloride 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
ezatiostat hydrochloride + [lenalidomide] 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
TLK-58747 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
TLK-60357 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
TLK-60404 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
TLK-60596 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Telik, Inc. - Pipeline Analysis 28
Telik, Inc. - Pipeline Products by Therapeutic Class 28
Telik, Inc. - Pipeline Products by Route of Administration 29
Telik, Inc. - Pipeline Products By Mechanism of Action 30
Telik, Inc. - Recent Pipeline Updates 31
Telik, Inc. - Dormant Projects 34
Telik, Inc. - Company Statement 35
Telik, Inc. - Locations And Subsidiaries 38
Head Office 38
Telik, Inc., Recent Developments 39
Telik, Inc.- Press Release 39
Jan 22, 2013: Telik Announces Preliminary Agreement On Design Of Phase III Registration Trial Of Telintra In Myelodysplastic Syndrome 39
Jan 11, 2013: Telik's Telintra Receives Orphan Designation From FDA For Treatment Of Myelodysplastic Syndrome 39
Dec 06, 2010: Telik Announces Final Positive Phase II Study Results Of Telintra In Patients With Myelodysplastic Syndrome 40
Jul 12, 2010: Telik Reports Publication Of Review On Inhibition Of Enzyme GSTP1-1 As Target For New Cancer Treatments 42
Jun 08, 2010: Telik Announces Positive Phase II Results Of Telintra Tablets In Patients With Myelodysplastic Syndrome 42
Jan 25, 2010: Telik Initiates Phase 1 Clinical Study Of Ezatiostat Hydrochloride (TELINTRA, TLK199) Tablets For The Treatment Of Myelodysplastic Syndrome 44
Financial Deals Landscape 45
Telik, Inc., Deals Summary 45
Telik, Inc., Pharmaceuticals and Healthcare, Deal Details 46
Partnerships 46
Telik Extends Its Agreement With The Translational Genomics 46
Telik Enters Into Agreement With The Translational Genomics 47
Licensing Agreements 48
Telik Enters Into Licensing Agreement With ReceptorBio 48
Telik Enters Into Licensing Agreement With Mount Sinai School of Medicine 49
SRI International Enters Into Licensing Agreement With Telik 50
Equity Offering 51
Telik Completes Private Placement Of Shares For $0.2 Million 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54



List of Tables

Telik, Inc., Key Information 5
Telik, Inc., Key Facts 5
Telik, Inc. - Pipeline by Indication, 2013 8
Telik, Inc. - Pipeline by Stage of Development, 2013 9
Telik, Inc. - Monotherapy Products in Pipeline, 2013 10
Telik, Inc. - Combination Treatment Modalities in Pipeline, 2013 11
Telik, Inc. - Phase III, 2013 12
Telik, Inc. - Phase II, 2013 13
Telik, Inc. - Phase I, 2013 14
Telik, Inc. - Pre-Clinical, 2013 15
Telik, Inc. - Pipeline By Therapeutic Class, 2013 28
Telik, Inc. - Pipeline By Route of Administration, 2013 29
Telik, Inc. - Pipeline Products By Mechanism of Action, 2013 30
Telik, Inc. - Recent Pipeline Updates, 2013 31
Telik, Inc. - Dormant Developmental Projects,2013 34
Telik, Inc., Deals Summary 45
Telik Extends Its Agreement With The Translational Genomics 46
Telik Enters Into Agreement With The Translational Genomics 47
Telik Enters Into Licensing Agreement With ReceptorBio 48
Telik Enters Into Licensing Agreement With Mount Sinai School of Medicine 49
SRI International Enters Into Licensing Agreement With Telik 50
Telik Completes Private Placement Of Shares For $0.2 Million 51



List of Figures

Telik, Inc. - Pipeline by Indication, 2013 7
Telik, Inc. - Pipeline by Stage of Development, 2013 9
Telik, Inc. - Monotherapy Products in Pipeline, 2013 10
Telik, Inc. - Combination Treatment Modalities in Pipeline, 2013 11
Telik, Inc. - Pipeline By Therapeutic Class, 2013 28
Telik, Inc. - Pipeline By Route of Administration, 2013 29
Telik, Inc. - Pipeline Products By Mechanism of Action, 2013 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.